Trabajos publicados derivados de MULTITEREB:
​
​
1) Deletion of a Pathogenic Mutation-Containing Exon of COL7A1 Allows Clonal Gene Editing Correction of RDEB Patient Epidermal Stem Cells.
Mencía A, Chamorro C, Bonafont J, Duarte B, Holguin A, Illera N, Escámez MJ, Hauser I, Del Río M, Larcher F, Murillas R
Mol Ther Nucleic Acids 2018.11:68-78. PMID 27045209.
IF: 5,66 Q1 (D2) Medicine, Research and Experimental
Open Access: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5852297/pdf/main.pdf
e-archivos UC3M: https://e-archivo.uc3m.es/handle/10016/28742
2) Fibroblasts activation and abnormal extracellular matrix remodelling as common hallmarks in three cancer-prone genodermatoses.
Chacón-Solano E, León C, Díaz F, García-García F, García M, Escámez MJ, Guerrero-Aspizua S, Conti CJ, Mencía Á, Martínez-Santamaría L, Llames S, Pévida M, Carbonell-Caballero J, Puig-Butillé JA, Maseda R, Puig S, de Lucas R, Baselga E, Larcher F, Dopazo J, Del Río M.
Br J Dermatol 2019. doi: 10.1111/bjd.17698. PMID 30693469.
IF: 6,129 Q1 (D1) Dermatology
Open Access: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850467/pdf/BJD-181-512.pdf
e-archivos UC3M: https://e-archivo.uc3m.es/handle/10016/28743
3) Clinically-relevant correction of Recessive Dystrophic Epidermolysis Bullosa by dual sgRNA CRISPR/Cas9-mediated gene editing.
Bonafont J, Mencía Á, García M, Torres R, Rodríguez-Perales S, Carretero M, Chacón-Solano E, Modamio-Høybjør S, Marinas L, León C, Escamez MJ, Hausser I, Del Río M, Murillas R y Larcher F.
Molecular Therapy 2019. 27(5):986-998. doi: 10.1016/j.ymthe.2019.03.007. PMID: 30930113.
IF: 7,008 Q1 (D1) Biotechnology and Applied Microbiology
Open Access: https://www.cell.com/action/showPdf?pii=S1525-0016%2819%2930093-0
e-archivos UC3M: https://e-archivo.uc3m.es/handle/10016/28318
4) Safety and efficacy outcomes for lentiviral autologous fibroblast gene therapy in adults with recessive dystrophic epidermolysis bullosa. Journal of clinical investigation Insight.
Lwin SM, Syed F, Di W-L, Kadiyirire T, Liu L, Guy A, Petrova A, Abdul-Wahab A, Reid F, Phillips R, Elstad M, Georgiadis C, Aristodemou S, Lovell PA, McMillan JR, Mee J, Miskinyte S, Titeux M, Ozoemena L, Pramanik R, Serrano S, Rowles R, Maurin C, Orrin E, Martinez-Queipo M, Rashidghamat E, Tziotzios C, Onoufriadis A, Chen M, Chan L, Farzaneh F, Del Río M, Tolar J, Bauer J W, Larcher F, Antoniou MN, Hovnanian A, Thrasher AJ, Mellerio JE, Qasim W, McGrath JA.
Journal of clinical investigation Insight 2019. Jun 6;4(11).
IF: 6.014 Q1 (D1) Medicine, Research & Experimental
Open Access: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6629162/pdf/jciinsight-4-126243.pdf
5) Epidemiology and natural history of cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa patients: twenty years' experience of a reference centre in Spain.
Castelo B, Viñal D, Maseda R, Ostios L, Sánchez D, García-Salvatierra B, Escámez MJ, Martínez-Santamaría L, Del Río M, Mora-Rillo M, Vilches Y, Beato MJ, López Gutiérrez JC, Romero N, Santos C, Miranda J, de Lucas R.
Clinical and Translational Oncology 2019. Mar 12. doi: 10.1007/s12094-019-02073-3. PMID: 30864020
IF: 2,392 Q3 (D7) Oncology
6) Human plasma gels: Their preparation and rheological characterization for cell culture applications in tissue engineering.
Barreda L, Marcet I, Llames S, Pevida M, García-Pérez E, Meana Á, Rendueles M, Díaz M.
J Mech Behav Biomed Mater. 2019 Jan; 89:107-113.
IF: 3,239 Q1 (D3) Biomedical Engineering
7) Clinical Practice Guidelines for Epidermolysis Bullosa Laboratory Diagnosis.
Has C, Liu L, Bolling M, Charlesworth AV, El Hachem M, Escámez MJ, Fuentes I, Büchel S, Hiremagalore R, Pohla-Gubo G, van den Akker P, Wertheim-Tysarowska K, Zambruno G.
Br J Dermatol. 2020. 182(3):574-592. PMID: 31090061 doi: 10.1111/bjd.18128.
IF: 7,000 Q1 (D1) Dermatology
Open Access: https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjd.18128
Guerrero-Aspizua S, González-Masa A, Conti CJ, García M, Chacón-Solano E, Larcher F, Del Río M.
Int J Mol Sci. 2020. 21(6):1951. PMID: 32178458 doi: 10.3390/ijms21061951.
IF: 4,556 Q1 (D3) Biochemestry and Molecular Biology
Open Access: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139348/pdf/ijms-21-01951.pdf
9) Raloxifene and n-Acetylcysteine Ameliorate TGF-Signalling in Fibroblasts from Patients with Recessive Dominant Epidermolysis Bullosa.
Aguado T, García M, García A, Ferrer-Mayorga G, Martínez-Santamaría L, Del Río M, Botella LM, Sánchez-Puelles JM.
Cells 2020. 9(9):2108. PMID: 32947957 doi: 10.3390/cells9092108.
IF: 4,366 Q2 (D4) Cell Biology
Open Access: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565802/pdf/cells-09-02108.pdf
10) Transcriptomic analysis of a diabetic skin-humanized mouse model dissects molecular pathways underlying the delayed wound healing response.
León C, García-García F, Llames S, García-Pérez E, Carretero M, Arriba MC, Dopazo J, Marcela Del Río M *, Escámez MJ *, Martínez-Santamaría L.
Genes (Basel) 2020. 2(1):47. PMID: 33396192 doi: 10.3390/genes12010047.
IF: 3,759 Q2 (D4)Genetics and Hereditary
Open Acces: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7824036/pdf/genes-12-00047.pdf
11) Formyl Peptide Receptor 2 DNA aptamers for targeted therapy of wound repair.
Arriba MC, Fernández G, Chacón-Solano E, Martínez-Santamaría L, Illera N, Carrión R, Martín M, Larcher F, González V, Del Río M, Carretero M. J Invest Dermatol. En revision editorial (JID-2020-0573).
IF: 7,143 Q1(D1) Dermatology
Otras publicaciones
1) CRISPR/Cas9-Mediated In Situ Correction of LAMB3 Gene in Keratinocytes Derived from a Junctional Epidermolysis Bullosa Patient
Benati D, Miselli F, Cocchiarella F, Patrizi C, Carretero M, Baldassarri S, Ammendola V, Has C, Colloca S, Del Río M, Larcher F, Recchia A. Mol Ther. 2018 Nov 7; 26(11):2592-2603 Pubmed
IF: 7,008 Q1 (D1) Biotechnology and Applied Microbiology
​
2) Efficient CRISPR-Cas9-Mediated Gene Ablation in Human Keratinocytes to Recapitulate Genodermatoses: Modeling of Netherton Syndrome.
Gálvez V, Chacón-Solano E, Bonafont J, Mencía Á, Di WL, Murillas R, Llames S, Vicente A, Del Rio M, Carretero M, Larcher F.
Mol Ther Methods Clin Dev. 2020 Jun 11;18:280-290. doi: 10.1016/j.omtm.2020.05.031. PMID: 32637457; PMCID: PMC7329935. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7329935/pdf/main.pdf
​
3) Assessment of the risk and characterization of non-melanoma skin cancer in Kindler syndrome: study of a series of 91 patients.
Guerrero-Aspizua S, Conti CJ, Escamez MJ, Castiglia D, Zambruno G, Youssefian L, Vahidnezhad H, Requena L, Itin P, Tadini G, Yordanova I, Martin L, Uitto J, Has C, Del Rio M.
Orphanet J Rare Dis. 2019 Jul 24;14(1):183. doi: 10.1186/s13023-019-1158-6. PMID: 31340837; PMCID: PMC6657209.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657209/pdf/13023_2019_Article_1158.pdf
​
4) Beneficial Effect of Systemic Allogeneic Adipose Derived Mesenchymal Cells on the Clinical, Inflammatory and Immunologic Status of a Patient With Recessive Dystrophic Epidermolysis Bullosa: A Case Report.
Maseda R, Martínez-Santamaría L, Sacedón R, Butta N, de Arriba MDC, García-Barcenilla S, García M, Illera N, Pérez-Conde I, Carretero M, Jiménez E, Melen G, Borobia AM, Jiménez-Yuste V, Vicente Á, Del Río M, de Lucas R, Escámez MJ.
Front Med (Lausanne). 2020 Nov 26;7:576558. doi: 10.3389/fmed.2
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726418/pdf/fmed-07-576558.pdf
​
5) Combined adipose mesenchymal stromal cell advanced therapy resolved a recalcitrant leg ulcer in an 85-year-old patient. Regen Med.
Martínez-Santamaría L, Cárcamo C, García-Pardo L, García-Arranz M, Melen G, Guerrero-Aspizua S, Llanos L, Río MD, García-Olmo D, Escámez MJ.
2020 Sep;15(9):2053-2065. doi: 10.2217/rme-2020-0139. Epub 2020 Nov 27. PMID: 33245008.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726418/pdf/fmed-07-576558.pdf
Libros y Capítulos de Libro
​
1) Bioprinting for Skin.
Quílez C, de Aranda Izuzquiza G, García M, López V, Montero A, Valencia L, Velasco D.
In Crook J (eds) 3D Bioprinting. Methods in Molecular Biology. Humana, New York, NY. 2020. Vol 2140: 263 pp. ISBN 978-1-0716-0519-6. PMID: 32207115 doi: 10.1007/978-1-0716-0520-2_14.
https://link.springer.com/protocol/10.1007%2F978-1-0716-0520-2_14
2) 15-Foodomics evaluation of genetically modified organisms.
León C, Cifuentes A.
In Pico Y (eds) Chemical Analysis of Food 2nd Ed. 2020. Academic Press: 657-695. ISBN 9780128132661. https://doi.org/10.1016/B978-0-12-813266-1.00015-2.
https://www.sciencedirect.com/science/article/pii/B9780128132661000152?via%3Dihub
3) Medicina, ciencia y realidad de las enfermedades raras/ medicine, science and reality of rare diseases.
Fillat C, del Río M, Martínez-Santamaría L, Bueren JA.
Terapias avanzadas en enfermedades raras. Arbor, [S.l.], v. 194, n. 789, p. a467, nov. 2018. ISSN 1988-303X. doi:http://dx.doi.org/10.3989/arbor.2018.789n3009.
http://arbor.revistas.csic.es/index.php/arbor/article/view/2280
​